시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 급성 편두통 치료 시장 분석 및 예측(-2034년) : 유형, 제품, 기술, 용도, 최종 사용자, 구성, 제형, 디바이스, 프로세스, 솔루션
Acute Migraine Treatment Market Analysis and Forecast to 2034: Type, Product, Technology, Application, End User, Component, Form, Device, Process, Solutions
상품코드 : 1740629
리서치사 : Global Insight Services LLC
발행일 : 2025년 06월
페이지 정보 : 영문 331 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,750 ￦ 6,898,000
Single User License help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능하며, 인쇄는 가능합니다.
US $ 5,750 ￦ 8,351,000
Site License help
PDF, Excel 보고서를 동일 기업(국가)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,750 ￦ 9,803,000
Enterprise License help
PDF, Excel 보고서를 동일 기업의 전 세계 모든분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 급성 편두통 치료 시장 규모는 2024년 29억 달러에서 2034년에는 45억 달러로 이를것으로 예측되고 CAGR 약 4.5%로 성장할 것으로 전망됩니다. 이 시장은 편두통 증상 완화를 목표로 하는 약물 및 비약물적 치료법을 포함합니다. 이는 트립탄, 비스테로이드성 항염증제(NSAIDs), 신흥 CGRP 억제제, 신경조절 장치와 같은 대체 치료법을 포함합니다. 이 시장은 편두통 유병률 증가, 인식 향상, 치료 방법의 발전에 의해 주도되고 있습니다. 혁신은 빠른 완화, 부작용 감소, 개인 맞춤형 치료에 초점을 맞추며, 편두통 환자의 다양한 요구를 충족시키기 위해 노력하고 있습니다.

시장 개요 :

급성 편두통 치료 시장은 편두통 유병률 증가와 빠른 완화 솔루션에 대한 수요로 인해 역동적인 변화를 겪고 있습니다. 제약 부문이 시장을 주도하며, 트립탄과 CGRP(칼시토닌 유전자 관련 펩타이드) 수용체 억제제가 주를 이룹니다. 이 약물은 표적화된 완화 효과를 제공하며, 효능과 빠른 작용 발현으로 인해 선호되는 치료법으로 자리 잡았습니다. 이 부문의 우위는 약물 제형 및 투여 메커니즘의 지속적인 개선으로 환자 순응도와 치료 결과를 향상시키기 때문입니다. 신규 부부문인 비약물적 치료법(신경조절 장치 및 디지털 치료제 등)은 비침습적 특성 및 약물 과다 사용 감소 잠재력으로 인해 주목받고 있습니다. 이러한 혁신은 특히 전통적 약물에 금기 사항이 있는 환자를 대상으로 대체 치료 옵션을 제공함으로써 시장에 큰 영향을 미칠 것으로 예상됩니다. 개인화 의료 접근법과 원격의료 플랫폼의 통합은 접근성 확대와 치료 경로 최적화를 통해 시장 확대를 가속화할 것으로 전망됩니다.

주요 동향 및 촉진요인 :

급성 편두통 치료 시장은 제약 연구의 진전과 전 세계적으로 편두통의 유병률 증가에 힘입어 눈에 띄는 성장을 기록하고 있습니다. 주요 트렌드에는 CGRP 억제제와 같은 새로운 치료제의 개발이 포함되며, 이는 표적화된 완화 효과와 부작용이 적은 장점을 제공합니다. 디지털 의료 기술의 통합은 환자 관리 개선을 촉진하고 있으며, 앱과 웨어러블 기기를 통해 실시간 모니터링과 맞춤형 치료 계획이 가능해지고 있습니다. 시장 확대의 주요 요인으로는 편두통이 심각한 신경학적 질환으로 인식되는 정도가 높아지고 효과적이고 빠른 작용을 보이는 치료제에 대한 수요가 증가하고 있다는 점이 있습니다. 편두통이 의료 시스템에 미치는 부담이 증가함에 따라 혁신적인 치료법 개발과 치료 접근성 개선에 대한 투자가 촉진되고 있습니다. 또한 인구 고령화와 생활 방식의 변화 등 인구 구조적 변화도 편두통 발생률 증가에 기여하고 있습니다. 신흥 시장에서 의료 인프라가 개선되고 고급 치료에 대한 수요가 급증함에 따라 다양한 기회가 존재합니다. 환자 교육 및 홍보 프로그램에 투자하는 기업은 경쟁 우위를 확보할 가능성이 높습니다. 또한 제약 회사와 기술 기업 간의 협력은 혁신을 촉진해 더 포괄적이고 효과적인 치료 솔루션을 이끌 것으로 예상됩니다.

주요 억제요인 및 도전 :

급성 편두통 치료 시장은 현재 여러 주요 억제요인과 도전 과제에 직면해 있습니다. 주요 억제요인은 새로운 치료 옵션의 높은 비용으로, 이는 저소득층 환자의 접근성을 제한합니다. 또한 엄격한 규제 요건은 신약 승인 과정을 지연시켜 시장 진입을 방해하고 있습니다. 또한 특정 치료법의 잠재적 부작용은 환자들 사이에서 사용과 수요를 억제해 전체 시장 성장을 저해합니다. 고급 치료 옵션에 대한 인식과 교육의 부족도 활용도를 낮추는 요인으로 작용합니다. 또한 대체 치료법과 일반 의약품 솔루션의 존재는 강력한 경쟁을 유발해 환자들이 처방약 치료를 회피하게 만들 수 있습니다. 이러한 과제들은 종합적으로 급성 편두통 치료 솔루션의 시장 확장 및 채택을 방해하고 있습니다.

목차

제1장 급성 편두통 치료 시장 개요

제2장 주요 요약

제3장 시장에 관한 중요 인사이트

제4장 급성 편두통 치료 시장 전망

제5장 급성 편두통 치료 시장의 전략

제6장 급성 편두통 치료 시장 규모

제7장 급성 편두통 치료 시장 : 유형별

제8장 급성 편두통 치료 시장 : 제품별

제9장 급성 편두통 치료 시장 : 기술별

제10장 급성 편두통 치료 시장 : 용도별

제11장 급성 편두통 치료 시장 : 최종 사용자별

제12장 급성 편두통 치료 시장 : 구성별

제13장 급성 편두통 치료시장 : 제형별

제14장 급성 편두통 치료 시장 : 디바이스별

제15장 급성 편두통 치료 시장 : 프로세스별

제16장 급성 편두통 치료 시장 : 솔루션별

제17장 급성 편두통 치료 시장 : 지역별

제18장 경쟁 구도

제19장 기업 프로파일

HBR
영문 목차

영문목차

Acute Migraine Treatment Market is anticipated to expand from $2.9 billion in 2024 to $4.5 billion by 2034, growing at a CAGR of approximately 4.5%. The market encompasses pharmaceutical and non-pharmaceutical interventions aimed at alleviating migraine symptoms. This includes triptans, NSAIDs, and emerging CGRP inhibitors, alongside alternative therapies like neuromodulation devices. The market is driven by rising migraine prevalence, increasing awareness, and advancements in treatment modalities. Innovations focus on rapid relief, reduced side effects, and personalized medicine, catering to the diverse needs of migraine sufferers.

Market Overview:

The Acute Migraine Treatment Market is witnessing a dynamic evolution, driven by the increasing prevalence of migraine and the demand for rapid relief solutions. The pharmaceutical segment leads the market, dominated by triptans and CGRP (calcitonin gene-related peptide) receptor antagonists, which offer targeted relief and have become the preferred choice due to their efficacy and quick onset of action. The dominance of this segment is attributed to ongoing advancements in drug formulations and delivery mechanisms, which enhance patient compliance and treatment outcomes. Emerging sub-segments, such as non-pharmacological therapies including neuromodulation devices and digital therapeutics, are gaining traction due to their non-invasive nature and potential to reduce medication overuse. These innovations are poised to significantly impact the market by offering alternative treatment options, particularly for patients with contraindications to traditional medications. The integration of personalized medicine approaches and telemedicine platforms is further anticipated to expand access and optimize treatment pathways.

Market Segmentation
TypeOral Medications, Nasal Spray, Injectable, Transdermal Patch
ProductTriptans, Ergot Alkaloids, NSAIDs, Anti-emetics, CGRP Inhibitors
TechnologyBiotechnology, Pharmaceuticals, Drug Delivery Systems
ApplicationHospital Pharmacies, Retail Pharmacies, Online Pharmacies
End UserHospitals, Clinics, Home Care
ComponentActive Pharmaceutical Ingredients, Excipients, Formulation
FormTablets, Capsules, Liquid, Powder
DeviceAutoinjectors, Prefilled Syringes, Nasal Devices
ProcessResearch and Development, Manufacturing, Quality Control
SolutionsPain Management, Symptom Relief, Prophylactic Treatment

Geographical Overview:

The acute migraine treatment market exhibits diverse growth patterns across various regions. North America dominates, driven by a high prevalence of migraines and advanced healthcare infrastructure. The region benefits from strong research initiatives and a high adoption rate of novel therapies. Europe follows, with substantial investments in healthcare and a focus on innovative treatment options. The region's regulatory environment supports the rapid approval of new medications. In Asia Pacific, the market is burgeoning due to rising healthcare awareness and increasing disposable incomes. The region's expanding middle class is driving demand for effective migraine treatments. Latin America presents a growing market, underpinned by improving healthcare access and rising migraine prevalence. Governments are investing in healthcare infrastructure, boosting market potential. The Middle East & Africa show promising growth prospects, with increasing recognition of migraine as a significant health concern. Efforts to enhance healthcare systems and access to treatment are underway. The region's market is poised for expansion as awareness and diagnosis rates improve. Each region's unique dynamics contribute to the global market's overall growth trajectory.

Recent Developments:

The Acute Migraine Treatment Market has experienced noteworthy developments in recent months. Pfizer completed its acquisition of Biohaven Pharmaceuticals, a move that significantly strengthens its position in the migraine treatment sector, particularly with the addition of Biohaven's CGRP-based therapies. In a strategic collaboration, Eli Lilly and Company announced a partnership with a leading digital health firm to enhance patient access to migraine treatments through innovative telemedicine solutions. The FDA approved a new acute migraine treatment from AbbVie, expanding their portfolio and offering patients a novel therapeutic option with potentially fewer side effects. Amgen unveiled an advanced formulation of its existing migraine medication, designed to improve efficacy and patient compliance, which is expected to be available in early 2024. Teva Pharmaceuticals reported a significant increase in the production capacity of its migraine treatments, addressing supply chain challenges and ensuring broader availability of their products across key markets. These developments underscore the dynamic nature of the acute migraine treatment landscape, highlighting both innovation and strategic growth.

Key Companies:

Biohaven Pharmaceuticals, Lundbeck, Teva Pharmaceuticals, Eli Lilly, Zosano Pharma, Impel Neuro Pharma, Alder Bio Pharmaceuticals, Satsuma Pharmaceuticals, Axsome Therapeutics, Supernus Pharmaceuticals, Tonix Pharmaceuticals, Aptinyx, Reata Pharmaceuticals, Cerecor, Osmotica Pharmaceuticals, Revance Therapeutics, Acorda Therapeutics, Karyopharm Therapeutics, Minerva Neurosciences, Novan

Key Trends and Drivers:

The acute migraine treatment market is experiencing notable growth fueled by advancements in pharmaceutical research and an increasing prevalence of migraines globally. Key trends include the development of novel therapeutics, such as CGRP inhibitors, which offer targeted relief and fewer side effects. The integration of digital health technologies is enhancing patient management, with apps and wearable devices providing real-time monitoring and personalized treatment plans. Drivers of market expansion include rising awareness about migraine as a serious neurological condition and the growing demand for effective, rapid-acting treatments. The increasing burden of migraine on healthcare systems is prompting investment in innovative therapies and improved access to care. Furthermore, demographic shifts, including an aging population and lifestyle changes, are contributing to higher migraine incidence rates. Opportunities abound in emerging markets where healthcare infrastructure is improving and demand for advanced treatments is escalating. Companies investing in patient education and outreach programs are likely to gain a competitive edge. Additionally, partnerships between pharmaceutical firms and technology companies are expected to drive innovation, leading to more comprehensive and effective treatment solutions.

Key Restraints and Challenges:

The acute migraine treatment market currently encounters several significant restraints and challenges. A primary restraint is the high cost of novel therapeutic options, which limits accessibility for patients in lower-income brackets. Moreover, the market is burdened by stringent regulatory requirements that prolong the approval process for new drugs, hindering timely market entry. Additionally, the potential side effects of certain treatments deter usage and demand among patients, impacting overall market growth. There is also a notable lack of awareness and education regarding advanced treatment options, leading to underutilization. Furthermore, the presence of alternative therapies and over-the-counter solutions provides stiff competition, often diverting patients away from prescription treatments. These challenges collectively impede the expansion and adoption of acute migraine treatment solutions in the market.

Sources:

World Health Organization (WHO), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), American Headache Society, Migraine Research Foundation, Global Burden of Disease Study, International Headache Society, World Federation of Neurology, European Headache Federation, National Institute for Health and Care Excellence (NICE), Brain & Behavior Research Foundation, American Academy of Neurology, International Headache Congress, European Headache and Migraine Trust International Congress, American Neurological Association Annual Meeting, Migraine Trust International Symposium, Society for Neuroscience Annual Meeting, National Headache Foundation

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Acute Migraine Treatment Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Acute Migraine Treatment Market Outlook

5: Acute Migraine Treatment Market Strategy

6: Acute Migraine Treatment Market Size

7: Acute Migraine Treatment Market, by Type

8: Acute Migraine Treatment Market, by Product

9: Acute Migraine Treatment Market, by Technology

10: Acute Migraine Treatment Market, by Application

11: Acute Migraine Treatment Market, by End User

12: Acute Migraine Treatment Market, by Component

13: Acute Migraine Treatment Market, by Form

14: Acute Migraine Treatment Market, by Device

15: Acute Migraine Treatment Market, by Process

16: Acute Migraine Treatment Market, by Solutions

17: Acute Migraine Treatment Market, by Region

18: Competitive Landscape

19: Company Profiles

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기